Brief: Iliad And Hvivo Sign LOI For Pivotal Phase 3 Trial Of BPZE1 Pertussis Vaccine
27/01/2025 13:12
Jan 27 (Reuters) - hVIVO PLC HVO.L :
* ILIAD AND HVIVO SIGN LOI FOR PIVOTAL PHASE 3 TRIAL OF
BPZE1
PERTUSSIS VACCINE FOLLOWING FDA MEETING
* ILIAD BIOTECHNOLOGIES: TRIAL ANTICIPATED FOR H2 2025
Source text: ID:nBwD3Djba
Further company coverage: HVO.L
(Reporting by SiddhiPrabhanjan Mahatole)
((SiddhiPrabhanjan.Mahatole@thomsonreuters.com;))